Why the study?
Does Growth hormone (GH) treatment improve endothelial function in Hypopituitary GH-deficient (GHD) men?
Does Growth hormone (GH) treatment improve endothelial function in Hypopituitary GH-deficient (GHD) men?
Answers are grounded in this paper and cite their sources.
Growth hormone treatment in GH-deficient men improves endothelial function as measured by flow-mediated endothelium-dependent dilation, defending against methodological critiques.
We would like to respond to the letter by Smith et al. (1), which questions the validity of the results (related to changes in endothelial function) in our paper entitled “Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults” (2). Our study has shown reversal of early morphological (intima-media thickening) and functional signs of atherosclerosis in the major arteries of hypopituitary GH-deficient (GHD) men. Endothelial function was assessed by noninvasive ultrasonic measurement of flow-mediated endothelium-dependent dilation (EDD) of the brachial artery, which improved with GH treatment. These results are in agreement with the results of Smith’s group (1). The hyperemic blood flow of the brachial artery after cuff release was also measured. The decreased response of brachial artery blood flow in GHD men compared with control men was reversed after 6 months of treatment (2). Smith et al. (1) suggested that the inconsistent changes in hyperemia-induced blood flow between groups might complicate the interpretation of EDD improvement with GH treatment. We disagree with the statement of Smith et al. (1) that for valid comparison of EDD between groups increases in blood flow should necessarily be of similar magnitude. Celermajer et al. (3) examined endothelial function in 238 healthy subjects by the same method and did not find any correlation between flow-mediated EDD and hyperemic blood flow increase. There are several observations that suggest that artery diameter changes in response to blood flow occlusion may be more than primarily flow-dependent responses. Corretti et al. (4) showed that occlusion of the forearm for 1, 3, and 5 min caused relatively similar flow increases on cuff release, whereas only 5 min of occlusion resulted in a significant increase of the arterial diameter. This suggests that other factors, such as ischemia produced by longer duration of occlusion, play some role in causing more marked vasodilation. Furthermore, it is known that endothelial dysfunction is not restricted only to large conduit peripheral arteries, but is also exerted at the level of resistance vessels (5). The presence of such a mechanism suggests that subjects at risk for atherosclerosis or atherosclerotic disease may not only have decreased EDD of major arteries but also decreased endothelium-dependent relaxation of resistance arteries that causes an increase in peripheral resistance and consequently decreased blood flow. Therefore, one of the feasible explanations of diminished blood flow in our GHD patients before treatment and its increase during replacement with GH could be improvement of endothelial dysfunction of resistance vessels with treatment. The finding of Böger et al. (6) that total peripheral resistance decreased by ∼30% with GH treatment in GHD adults supports this explanation. Instead of the conclusion of Smith et al. (1), we believe that mechanisms causing increased blood flow after cuff release are not related only to ischemic vasodilatory substances that have been produced during blood flow occlusion, but also depend on the endothelial function of resistance vessels. Our patients have been followed for 4 yr now. EDD results are consistent and do not show any unexpected changes with time (except the mentioned inexplicable worsening at 12 months). We would like to correct the misinterpretation in paragraph two of the letter by Smith et al. (1) relating to our reproducibility data of the EDD measurements. The intraoperator coefficient of variation of 8.3% refers to the calculated EDD (percentage change in brachial artery diameter) and not to the baseline arterial diameter measurement, and this was clearly stated in our paper (2). Thus, Smith et al.’s (1) interpretation of our EDD data are misleading. We observed an increase in brachial artery diameter (EDD) of 7.93% before treatment increasing to a maximum of 12.16% after 18 months of GH treatment. The coefficient of variation accounts for ±0.66% and ±1.01% variability, respectively, what is far below the 4% difference between EDD measurements before and after 18 months of treatment, and allows the conclusion that GH treatment had a beneficial effect on the endothelial function. Our considerable experience (for more than 7 yr) with measurement of endothelial function using the same method shows that our ultrasonic system permits acceptable resolution of arterial wall and adequate measurements of vessel diameter. Our experience with this method is in accordance with other authors who developed this noninvasive procedure (3, 7, 8). Therefore, we believe our results are methodologically sound and the interpretations correct and cannot be explained in the way suggested by Smith et al., but rather are a genuine effect of GH treatment.
No takes yet. Share an insight, caveat, or question.
Pfeifer et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: